Published online Jul 21, 2021. doi: 10.3748/wjg.v27.i27.4453
Peer-review started: February 21, 2021
First decision: May 13, 2021
Revised: May 16, 2021
Accepted: July 7, 2021
Article in press: July 7, 2021
Published online: July 21, 2021
Most hepatocellular carcinomas (HCCs) are hypervascular, with characteristic features of hepatic arterial supply to the tumor. The factors involved in tumor angiogenesis include angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), and vascular endothelial growth factor (VEGF).
Angiogenesis markers can be a potential biomarker.
To investigate the profiles of plasma levels of angiogenesis markers in patients with HCC and evaluate their roles in predicting overall survival (OS) and progression-free survival (PFS).
Plasma samples from 240 prospectively enrolled HCC patients in the very early to advanced stages were used to measure the levels of Ang-1, Ang-2, and VEGF. Their associations with clinical characteristics, OS, and PFS were analyzed.
The plasma level of Ang-2 correlated with liver function, tumor stage, and tumor invasiveness. Multivariable and propensity score-matched analyses revealed Ang-2 Levels with the highest predictive power for OS in patients with HCC.
The plasma levels of Ang-2 can be a better biomarker than AFP in predicting OS or RFS.
Identifying HCCs using circulating biomarkers that are sensitive to antiangiogenic therapy and predictive of OS and PFS could improve therapeutic approaches.